Ovarian cancer

Making its own rules—again

Authors


  • See original referenced article on pages 548–54, this issue.

Abstract

The field of ovarian cancer research has made marked progress in better understanding ovarian cancer and redefining its types. New information is putting into doubt that mutations in KRAS and/or BRAF always portend poor outcome, at least not in low-grade serous ovarian cancers.

Ancillary